Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement
Internal Medicine Journal · 30.09.2026
DOI: 10.1111/imj.70644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 30.09.2026. Verfasst von Aine Hurley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The LifeBlood Trust, Thompson Family Foundation, David Levene Foundation.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cell therapies directed against c luster of differentiation 19 ( CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt. Recipients of CAR T‐cells can present in various clinical settings, and few trials have prospectively assessed prevention and management of infection in this group. This position statement provides Australian and New Zealand clinicians with a rational approach to preventing, investigating and managing infections after CD19‐directed CAR T‐cell therapy for lymphoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand.
- Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.
- Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
ORCID-Profile: Aine Hurley, Philip George, Gemma Reynolds, Adam Stewart, Hang Quach, Nicole O'Leary, Andrea S Henden, Lynette Chee, Chan Y Cheah, Emily Blyth, Ben Teh, Monica Slavin, Michael Dickinson, Robert Weinkove
Förderung
- The LifeBlood Trust
- Thompson Family Foundation
- David Levene Foundation
Zitieren
APA
Hurley, A., George, P., Reynolds, G., Stewart, A., Quach, H., O'Leary, N., McQuilten, Z., Henden, A. S., Chee, L., Cheah, C. Y., Bupha-Intr, O., Blyth, E., Teh, B., Slavin, M., Dickinson, M., & Weinkove, R. (2026). Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement. Internal Medicine Journal. https://doi.org/10.1111/imj.70644
Vancouver
Hurley A, George P, Reynolds G, Stewart A, Quach H, O'Leary N, et al. Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement. Internal Medicine Journal. 2026. doi:10.1111/imj.70644
BibTeX
@article{Hurley2026,
author = {Hurley, Aine and George, Philip and Reynolds, Gemma and Stewart, Adam and Quach, Hang and O'Leary, Nicole and McQuilten, Zoe and Henden, Andrea S and Chee, Lynette and Cheah, Chan Y and Bupha-Intr, Olivia and Blyth, Emily and Teh, Ben and Slavin, Monica and Dickinson, Michael and Weinkove, Robert},
title = {Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70644}
}
EUVIMED